Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig + Axitinib/Lenvatinib in Advanced RCC
NCT04522323Phase 1Active, not recruiting
- Sponsor
- MedImmune
- Start
- Aug 2020
- Primary completion
- Sep 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of volrustomig in renal cell carcinoma (RCC) (2 arms), sponsored by MedImmune. Primary endpoints: Adverse Events and Serious Adverse Events, Dose Limiting Toxicities at 21 days and 3 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04522323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522323.